Burning Rock Biotech (BNR) Operating Leases: 2021-2025
- Burning Rock Biotech's Operating Leases was N/A to $17.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $17.9 million, marking a year-over-year change of. This contributed to the annual value of $7.2 million for FY2024, which is 312.90% up from last year.
- Per Burning Rock Biotech's latest filing, its Operating Leases stood at $17.9 million for Q2 2025, which was up 149.32% from $7.2 million recorded in Q4 2024.
- Burning Rock Biotech's Operating Leases' 5-year high stood at $17.9 million during Q2 2025, with a 5-year trough of $1.7 million in Q4 2023.
- For the 3-year period, Burning Rock Biotech's Operating Leases averaged around $8.9 million, with its median value being $7.2 million (2024).
- In the last 5 years, Burning Rock Biotech's Operating Leases tumbled by 76.43% in 2023 and then soared by 312.90% in 2024.
- Over the past 5 years, Burning Rock Biotech's Operating Leases (Quarterly) stood at $13.2 million in 2021, then tumbled by 44.34% to $7.4 million in 2022, then plummeted by 76.43% to $1.7 million in 2023, then surged by 312.90% to $7.2 million in 2024, then reached $17.9 million in 2025.
- Its Operating Leases stands at $17.9 million for Q2 2025, versus $7.2 million for Q4 2024 and $1.7 million for Q4 2023.
